Navigation Links
UV Flu Technologies Aggressively Paying Down Debt to Build Platform for Expected Growth in Consumer and Hospital Markets
Date:1/3/2012

CENTERVILLE, Mass., Jan. 3, 2012  /PRNewswire/ -- UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce it has dramatically improved its Balance Sheet over the last twelve months, as referenced by the recent filing of its Annual "K" for the Year ended September 30, 2011. In the report filed, the Company disclosed that Current Liabilities, which include notes and accounts payable, decreased to $284,636, a 59% reduction from the $691,639 level of a year ago. Stockholders' Equity increased $465,608 over the same period. Gross profit more than tripled to $75,780 over the period, even though results from Rx Air were not included for the full year.

"This report actually understates the progress we have made over the last several months," said Jack Lennon, President of UV Flu Technologies. "In March of this year, the Board of the Company decided to initiate a crash program to dramatically decrease corporate overhead and pay down debt, while increasing sales by focusing on our three key target markets, Consumer, Medical, and International Sales. We have continued to make progress in all three areas relative to sales, and our plans to pay down a significant amount of our existing debt are expected to be completed ahead of schedule. In addition, our ongoing review of every expense and liability made significant headway, resulting in a profit for the 4th quarter," said Mr. Lennon.

"We continue to cut overhead, and should be completed with our 12 month program in February. On the sales front, we have made extraordinary strides. Internationally, we are one of the only companies in the world, regardless of size, that has products approved for sale in Hospitals in the U.S., China and India. We will be announcing new distributors in the coming months, both in the U.S. and internationally, and our efforts on the consumer side, we feel, have the potential to make UV Flu the household name when referring to the control of Indoor Air Pollution," said Mr. Lennon.

Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's  ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.

About UV Flu Technologies, Inc. (OTCBB: UVFT)

UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.)  The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.

In addition, the Company's RxAir subsidiary in Dallas, TX, makes one of the worlds' finest lines of hospital-grade HEPA filtration products. The RX-3000, the Company's main product, is currently in almost 450 hospitals internationally, is FDA cleared as a Class II Medical Device, and has been shown to capture 99.99% of all airborne contaminants. The Company's product lines are in Hospitals, government buildings, casinos and restaurants around the world.

For more information, visit: www.uvflutech.com.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.

-----------------------------

John J. Lennon, President & CEO

Investor Information:
Toll-Free: 1-877-358-5455

Web: www.uvflutech.com


'/>"/>
SOURCE UV Flu Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MultiCell Technologies Receives Final Payment Under QTDP Program
2. Transdermal Drug Delivery - Technologies, Markets, and Companies
3. Pulmonary Drug Delivery Systems: Technologies and Global Markets
4. Veran Medical Technologies Launches New SPiN Driveā„¢ Application for Bi-Planar Virtual Fluoroscopy View
5. Heska Announces Exploration of New Technologies Through Strategic Collaboration with Entegrion, Inc.
6. China Medical Technologies Intends to Implement Debt Restructuring
7. OrthoAccel Technologies, Inc. Announces New Chief Financial Officer
8. HealthpointCapital Acquires Blue Belt Technologies, Inc. and Appoints Eric B. Timko as President and CEO
9. China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group
10. AirStrip Technologies Announces Home Health Collaboration With Qualcomm Life
11. CareFusion Showcases Medication Management Technologies at American Society for Health-System Pharmacists Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... of two Phase 2 trials of its RSV F protein ... child bearing age have been published in the journal ... have been shared in prior scientific conferences). The Company previously ... April 2014. Novavax is developing the RSV F Vaccine with ...
(Date:6/2/2017)... -- NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company focused ... positive biochemical outcomes related to more frequent hemodialysis with ... be presented at the ERA-EDTA Congress being held June ... The research was conducted by the ... Europe (KIHDNEy) Cohort team with ...
(Date:5/29/2017)... Biotechnology Ltd. (NASDAQ: APOP ; TASE: APOP), a ... of stem cells, today provided a corporate update and ... 31 st , 2017. "We are ... of 2017," said Dr. Shai Yarkoni, Chief Executive Officer. ... the first blood cancer patient in the recently initiated ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... June 27, 2017 , ... ... according to survey data released today by the American Society for Dermatologic ... indicates the percentage of consumers considering a cosmetic medical procedure has doubled ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... Harbour ... manage token assets on the Ethereum blockchain, has released their technical specifications . ... now, there has been little systematic approach for determining which offerings will garner the ...
(Date:6/27/2017)... ... June 27, 2017 , ... The Congressional Budget Office (CBO) projects ... replace the 2010 Patient Protection and Affordable Care Act (ACA), would result in 22 ... expected under current law. , More than 20 million Americans have gained health insurance ...
(Date:6/27/2017)... ... ... From June 20-22, EarQ and Widex held an exclusive training ... EarQ is headquartered. , Together, the organizations educate hearing care professionals on how ... the latest in hearing technology. At the event, EarQ members got an in-depth ...
(Date:6/27/2017)... ... ... Two residents from the Gardant-managed assisted living and memory care communities in South ... protect Medicaid funding. , The video, which was produced by the American Health Care ... Cathy Schwarz, a couple who is still able to see each other every day ...
Breaking Medicine News(10 mins):